Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Inclusion Criteria: All Cohorts: * Written informed consent * Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections was required and vaccination against Haemophilus influenzae infection is recommended prior to the start of treatment. * Weight of at least 35 kg Cohort 1 specific inclusion criteria: * Participants with a diagnosis of persistent or chronic primary ITP * Participants must have received at least 1 unique prior therapy administered with the intention to treat ITP * Sustained thrombocytopenia Cohort 2 specific inclusion criteria: * Participants with a diagnosis of primary CAD * Participants must have received at least 1 unique prior therapy administered with the intention to treat CAD * Laboratory evidence of ongoing hemolysis * Sustained anemia Exclusion Criteria: All cohorts: * Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations * Past or concomitant use of medications prohibited by the protocol * Known or suspected hereditary or acquired complement deficiency * History of primary or secondary immunodeficiency, including a positive HIV test result * Chronic infection with Hepatitis B or C virus * History of recurrent invasive infections caused by encapsulated organisms, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae * Presence or suspicion of any active infect…